{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:13:31Z","timestamp":1787505211322,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-024-05496-5","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T23:35:38Z","timestamp":1709768138000},"page":"2383-2389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Soluble urokinase plasminogen activator receptor (suPAR) in children with obesity or type 1 diabetes as a marker of endothelial dysfunction: a cross-sectional study"],"prefix":"10.1007","volume":"183","author":[{"given":"Eirini","family":"Kostopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Kalavrizioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Davoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xenophon","family":"Sinopidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Papachristou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios S.","family":"Goumenos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Dimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bessie E.","family":"Spiliotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9375-989X","authenticated-orcid":false,"given":"Marios","family":"Papasotiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"5496_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12916-019-1449-8","volume":"17","author":"M Di Cesare","year":"2019","unstructured":"Di Cesare M, Sori\u0107 M, Bovet P et al (2019) The epidemiological burden of obesity in childhood: a worldwide epidemic requiring urgent action. BMC Med 17:1\u201320. https:\/\/doi.org\/10.1186\/S12916-019-1449-8","journal-title":"BMC Med"},{"key":"5496_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/AJCN\/76.3.653","volume":"76","author":"SS Guo","year":"2002","unstructured":"Guo SS, Wu W, Chumlea WC, Roche AF (2002) Predicting overweight and obesity in adulthood from body mass index values in childhood and adolescence. Am J Clin Nutr 76:653\u2013658. https:\/\/doi.org\/10.1093\/AJCN\/76.3.653","journal-title":"Am J Clin Nutr"},{"key":"5496_CR3","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1542\/PEDS.2008-1284","volume":"123","author":"DS Freedman","year":"2009","unstructured":"Freedman DS, Dietz WH, Srinivasan SR, Berenson GS (2009) Risk factors and adult body mass index among overweight children: the Bogalusa Heart Study. Pediatrics 123:750\u2013757. https:\/\/doi.org\/10.1542\/PEDS.2008-1284","journal-title":"Pediatrics"},{"key":"5496_CR4","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/J.AMJCARD.2016.04.085","volume":"117","author":"MU Es","year":"2016","unstructured":"Es MU, \u015eenol S, Y\u00fcksel A, Karg\u00fcn K (2016) OP-042 endothelin-1 gene polymorphisms in patients with peripheral artery disease. Am J Cardiol 117:S17. https:\/\/doi.org\/10.1016\/J.AMJCARD.2016.04.085","journal-title":"Am J Cardiol"},{"key":"5496_CR5","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(21)00246-1","volume":"9","author":"B Van der Schueren","year":"2021","unstructured":"Van der Schueren B, Ellis D, Faradji RN et al (2021) Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol 9:776\u2013785. https:\/\/doi.org\/10.1016\/S2213-8587(21)00246-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5496_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1210\/ER.2017-00191","volume":"39","author":"KD Corbin","year":"2018","unstructured":"Corbin KD, Driscoll KA, Pratley RE et al (2018) Obesity in type 1 diabetes: pathophysiology, clinical impact, and mechanisms. Endocr Rev 39:629\u2013663. https:\/\/doi.org\/10.1210\/ER.2017-00191","journal-title":"Endocr Rev"},{"key":"5496_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/DIACARE.18.2.258","volume":"18","author":"R Klein","year":"1995","unstructured":"Klein R (1995) Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18:258\u2013268. https:\/\/doi.org\/10.2337\/DIACARE.18.2.258","journal-title":"Diabetes Care"},{"key":"5496_CR8","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1373\/CLINCHEM.2007.100156","volume":"54","author":"S De Ferranti","year":"2008","unstructured":"De Ferranti S, Mozaffarian D (2008) The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin Chem 54:945\u2013955. https:\/\/doi.org\/10.1373\/CLINCHEM.2007.100156","journal-title":"Clin Chem"},{"key":"5496_CR9","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.2337\/DB07-0784","volume":"56","author":"S Devaraj","year":"2007","unstructured":"Devaraj S, Cheung AT, Jialal I et al (2007) Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes 56:2790\u20132796. https:\/\/doi.org\/10.2337\/DB07-0784","journal-title":"Diabetes"},{"key":"5496_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1741-7015-10-2","volume":"10","author":"K Donadello","year":"2012","unstructured":"Donadello K, Scolletta S, Covajes C, Vincent JL (2012) suPAR as a prognostic biomarker in sepsis. BMC Med 10:1\u20139. https:\/\/doi.org\/10.1186\/1741-7015-10-2","journal-title":"BMC Med"},{"key":"5496_CR11","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1007\/S00125-013-2914-0","volume":"56","author":"A Heraclides","year":"2013","unstructured":"Heraclides A, Jensen TM, Rasmussen SS et al (2013) The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status. Diabetologia 56:1542\u20131546. https:\/\/doi.org\/10.1007\/S00125-013-2914-0","journal-title":"Diabetologia"},{"key":"5496_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000324587","volume":"4","author":"R Cancello","year":"2011","unstructured":"Cancello R, Rouault C, Guilhem G et al (2011) Urokinase plasminogen activator receptor in adipose tissue macrophages of morbidly obese subjects. Obes Facts 4:17\u201325. https:\/\/doi.org\/10.1159\/000324587","journal-title":"Obes Facts"},{"key":"5496_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/J.IJCARD.2016.11.201","volume":"228","author":"M Kosecik","year":"2017","unstructured":"Kosecik M, Dervisoglu P, Koroglu M et al (2017) Usefulness of soluble urokinase plasminogen activator receptor (suPAR) as an inflammatory biomarker in obese children. Int J Cardiol 228:158\u2013161. https:\/\/doi.org\/10.1016\/J.IJCARD.2016.11.201","journal-title":"Int J Cardiol"},{"key":"5496_CR14","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/J.CJCA.2015.03.023","volume":"31","author":"GW Hodges","year":"2015","unstructured":"Hodges GW, Bang CN, Wachtell K et al (2015) suPAR: a new biomarker for cardiovascular disease? Can J Cardiol 31:1293\u20131302. https:\/\/doi.org\/10.1016\/J.CJCA.2015.03.023","journal-title":"Can J Cardiol"},{"key":"5496_CR15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/J.RESP.2014.12.018","volume":"209","author":"A Wrotek","year":"2015","unstructured":"Wrotek A, Jackowska T (2015) The role of the soluble urokinase plasminogen activator (suPAR) in children with pneumonia. Respir Physiol Neurobiol 209:120\u2013123. https:\/\/doi.org\/10.1016\/J.RESP.2014.12.018","journal-title":"Respir Physiol Neurobiol"},{"key":"5496_CR16","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/S12098-016-2063-9","volume":"83","author":"MS El-Mekkawy","year":"2016","unstructured":"El-Mekkawy MS, Saleh NY, Sonbol AA (2016) Soluble urokinase plasminogen activator receptor: a new biomarker in the pediatric intensive care unit. Indian J Pediatr 83:661\u2013669. https:\/\/doi.org\/10.1007\/S12098-016-2063-9","journal-title":"Indian J Pediatr"},{"key":"5496_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.4103\/0971-9784.179588","volume":"19","author":"N Cyrille","year":"2016","unstructured":"Cyrille N, Villablanca PA, Ramakrishna H (2016) Soluble urokinase plasminogen activation receptor\u2013an emerging new biomarker of cardiovascular disease and critical illness. Ann Card Anaesth 19:214\u2013216. https:\/\/doi.org\/10.4103\/0971-9784.179588","journal-title":"Ann Card Anaesth"},{"key":"5496_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.23736\/S0026-4946.16.04461-3","volume":"71","author":"J So\u0142tysiak","year":"2019","unstructured":"So\u0142tysiak J, Zachwieja J, Benedyk A et al (2019) Circulating suPAR as a biomarker of disease severity in children with proteinuric glomerulonephritis. Minerva Pediatr 71:4\u201311. https:\/\/doi.org\/10.23736\/S0026-4946.16.04461-3","journal-title":"Minerva Pediatr"},{"issue":"9","key":"5496_CR19","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.2337\/dci18-0023","volume":"41","author":"JL Chiang","year":"2018","unstructured":"Chiang JL, Maahs DM, Garvey KC et al (2018) Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association. Diabetes Care 41(9):2026\u20132044. https:\/\/doi.org\/10.2337\/dci18-0023","journal-title":"Diabetes Care"},{"issue":"1","key":"5496_CR20","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1186\/s13104-017-2983-0","volume":"10","author":"LN Anderson","year":"2017","unstructured":"Anderson LN, Carsley S, Lebovic G, Borkhoff CM, Maguire JL, Parkin PC, Birken CS (2017) Misclassification of child body mass index from cut-points defined by rounded percentiles instead of Z-scores. BMC Res Notes 10(1):639. https:\/\/doi.org\/10.1186\/s13104-017-2983-0","journal-title":"BMC Res Notes"},{"key":"5496_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/S00125-018-4711-2","volume":"62","author":"JL Harding","year":"2019","unstructured":"Harding JL, Pavkov ME, Magliano DJ et al (2019) Global trends in diabetes complications: a review of current evidence. Diabetologia 62:3\u201316. https:\/\/doi.org\/10.1007\/S00125-018-4711-2","journal-title":"Diabetologia"},{"key":"5496_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4137\/BMI.S19876","volume":"9","author":"TH Haupt","year":"2014","unstructured":"Haupt TH, Kallemose T, Ladelund S et al (2014) Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population. Biomark Insights 9:91\u2013100. https:\/\/doi.org\/10.4137\/BMI.S19876","journal-title":"Biomark Insights"},{"key":"5496_CR23","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1016\/J.IJCARD.2012.07.018","volume":"167","author":"S Lyngb\u00e6k","year":"2013","unstructured":"Lyngb\u00e6k S, Marott JL, Sehestedt T et al (2013) Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk score. Int J Cardiol 167:2904\u20132911. https:\/\/doi.org\/10.1016\/J.IJCARD.2012.07.018","journal-title":"Int J Cardiol"},{"key":"5496_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/J.JSAMS.2017.06.018","volume":"21","author":"C Rohde","year":"2018","unstructured":"Rohde C, Polcwiartek C, Andersen E et al (2018) Effect of a physical activity intervention on suPAR levels: a randomized controlled trial. J Sci Med Sport 21:286\u2013290. https:\/\/doi.org\/10.1016\/J.JSAMS.2017.06.018","journal-title":"J Sci Med Sport"},{"key":"5496_CR25","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/J.IJCARD.2012.03.040","volume":"167","author":"S Lyngb\u00e6k","year":"2013","unstructured":"Lyngb\u00e6k S, Sehestedt T, Marott JL et al (2013) CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol 167:781\u2013785. https:\/\/doi.org\/10.1016\/J.IJCARD.2012.03.040","journal-title":"Int J Cardiol"},{"key":"5496_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/POSTGRADMEDJ-2018-135839","volume":"94","author":"L Hamie","year":"2018","unstructured":"Hamie L, Daoud G, Nemer G et al (2018) SuPAR, an emerging biomarker in kidney and inflammatory diseases. Postgrad Med J 94:517\u2013524. https:\/\/doi.org\/10.1136\/POSTGRADMEDJ-2018-135839","journal-title":"Postgrad Med J"},{"key":"5496_CR27","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1007\/S00134-012-2613-1","volume":"38","author":"Y Van Der Backes","year":"2012","unstructured":"Van Der Backes Y, Mackie DP et al (2012) Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med 38:1418\u20131428. https:\/\/doi.org\/10.1007\/S00134-012-2613-1","journal-title":"Intensive Care Med"},{"key":"5496_CR28","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1161\/STROKEAHA.112.664094","volume":"43","author":"A Edsfeldt","year":"2012","unstructured":"Edsfeldt A, Nitulescu M, Grufman H et al (2012) Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Stroke 43:3305\u20133312. https:\/\/doi.org\/10.1161\/STROKEAHA.112.664094","journal-title":"Stroke"},{"key":"5496_CR29","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/J.1365-2796.2010.02252.X","volume":"268","author":"J Eugen-Olsen","year":"2010","unstructured":"Eugen-Olsen J, Andersen O, Linneberg A et al (2010) Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 268:296\u2013308. https:\/\/doi.org\/10.1111\/J.1365-2796.2010.02252.X","journal-title":"J Intern Med"},{"key":"5496_CR30","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/J.ATHEROSCLEROSIS.2011.10.039","volume":"220","author":"M Persson","year":"2012","unstructured":"Persson M, Engstr\u00f6m G, Bj\u00f6rkbacka H, Hedblad B (2012) Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malm\u00f6 Diet and Cancer Study. Atherosclerosis 220:502\u2013505. https:\/\/doi.org\/10.1016\/J.ATHEROSCLEROSIS.2011.10.039","journal-title":"Atherosclerosis"},{"key":"5496_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1089\/THER.2014.0027","volume":"5","author":"M Rundgren","year":"2015","unstructured":"Rundgren M, Lyngbaek S, Fisker H, Friberg H (2015) The inflammatory marker suPAR after cardiac arrest. Ther Hypothermia Temp Manag 5:89\u201394. https:\/\/doi.org\/10.1089\/THER.2014.0027","journal-title":"Ther Hypothermia Temp Manag"},{"key":"5496_CR32","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/J.EKIR.2018.05.004","volume":"3","author":"C Torino","year":"2018","unstructured":"Torino C, Pizzini P, Cutrupi S et al (2018) Soluble urokinase plasminogen activator receptor (suPAR) and all-cause and cardiovascular mortality in diverse hemodialysis patients. Kidney Int Rep 3:1100\u20131109. https:\/\/doi.org\/10.1016\/J.EKIR.2018.05.004","journal-title":"Kidney Int Rep"},{"key":"5496_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4103\/IJMR.IJMR_1195_15","volume":"145","author":"U Can","year":"2017","unstructured":"Can U, Buyukinan M, Yerlikaya FH (2017) Serum levels of soluble urokinase plasminogen activator receptor as a new inflammatory marker in adolescent obesity. Indian J Med Res 145:327\u2013333. https:\/\/doi.org\/10.4103\/IJMR.IJMR_1195_15","journal-title":"Indian J Med Res"},{"issue":"4","key":"5496_CR34","doi-asserted-by":"publisher","first-page":"e836","DOI":"10.1097\/PR9.0000000000000836","volume":"5","author":"H Raff","year":"2020","unstructured":"Raff H, Phillips JM, Simpson PM et al (2020) Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity. Pain Rep 5(4):e836. https:\/\/doi.org\/10.1097\/PR9.0000000000000836","journal-title":"Pain Rep"},{"key":"5496_CR35","doi-asserted-by":"publisher","first-page":"25234","DOI":"10.3390\/IJMS161025234","volume":"16","author":"Y Kayama","year":"2015","unstructured":"Kayama Y, Raaz U, Jagger A et al (2015) Diabetic cardiovascular disease induced by oxidative stress. Int J Mol Sci 16:25234. https:\/\/doi.org\/10.3390\/IJMS161025234","journal-title":"Int J Mol Sci"},{"issue":"9","key":"5496_CR36","doi-asserted-by":"publisher","first-page":"e0138718","DOI":"10.1371\/JOURNAL.PONE.0138718","volume":"10","author":"SM Guo","year":"2015","unstructured":"Guo SM, Han M, Chen MX et al (2015) Soluble urokinase receptor levels are correlated with focal segmental glomerulosclerosis lesions in IgA nephropathy: a cohort study from China. PLoS ONE 10(9):e0138718. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0138718","journal-title":"PLoS ONE"},{"key":"5496_CR37","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/S00424-017-2026-7","volume":"469","author":"M Zeier","year":"2017","unstructured":"Zeier M, Reiser J (2017) suPAR and chronic kidney disease-a podocyte story. Pflugers Arch 469:1017\u20131020. https:\/\/doi.org\/10.1007\/S00424-017-2026-7","journal-title":"Pflugers Arch"},{"key":"5496_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/J.ARCMED.2019.08.007","volume":"50","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Ren J, Li P et al (2019) Expression of urokinase-type plasminogen activator receptor and its soluble form in type 2 diabetic kidney disease. Arch Med Res 50:249\u2013256. https:\/\/doi.org\/10.1016\/J.ARCMED.2019.08.007","journal-title":"Arch Med Res"},{"key":"5496_CR39","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/J.PHRS.2015.09.017","volume":"102","author":"N Prevete","year":"2015","unstructured":"Prevete N, Liotti F, Marone G et al (2015) Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth. Pharmacol Res 102:184\u2013191. https:\/\/doi.org\/10.1016\/J.PHRS.2015.09.017","journal-title":"Pharmacol Res"},{"key":"5496_CR40","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1111\/JCMM.14004","volume":"23","author":"M Dal Monte","year":"2019","unstructured":"Dal Monte M, Cammalleri M, Pecci V et al (2019) Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy. J Cell Mol Med 23:1034\u20131049. https:\/\/doi.org\/10.1111\/JCMM.14004","journal-title":"J Cell Mol Med"},{"key":"5496_CR41","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/JOIM.12269","volume":"277","author":"S Theilade","year":"2015","unstructured":"Theilade S, Lyngb\u00e6k S, Hansen TW et al (2015) Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. J Intern Med 277:362\u2013371. https:\/\/doi.org\/10.1111\/JOIM.12269","journal-title":"J Intern Med"},{"key":"5496_CR42","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.2337\/DC18-1427","volume":"42","author":"VR Curovic","year":"2019","unstructured":"Curovic VR, Theilade S, Winther SA et al (2019) Soluble urokinase plasminogen activator receptor predicts cardiovascular events, kidney function decline, and mortality in patients with type 1 diabetes. Diabetes Care 42:1112\u20131119. https:\/\/doi.org\/10.2337\/DC18-1427","journal-title":"Diabetes Care"},{"key":"5496_CR43","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/J.JDIACOMP.2019.06.001","volume":"33","author":"EM Sherif","year":"2019","unstructured":"Sherif EM, El Maksood AAA, Youssef OI et al (2019) Soluble urokinase plasminogen activator receptor in type 1 diabetic children, relation to vascular complications. J Diabetes Complications 33:628\u2013633. https:\/\/doi.org\/10.1016\/J.JDIACOMP.2019.06.001","journal-title":"J Diabetes Complications"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-024-05496-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-024-05496-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-024-05496-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:25:25Z","timestamp":1713745525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-024-05496-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["5496"],"URL":"https:\/\/doi.org\/10.1007\/s00431-024-05496-5","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"26 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Research Ethics Committee of the University Hospital of Patras (Date: 02\/09\/15, Number: 353).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"An informed consent was provided by the parents or legal representatives of all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}